Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Eli Lily On Thursday report Profit and profits in the first quarter who led the estimates as a demand for it Weight loss and diabetes drugs It increased, but downgraded a full decent income management due to allegations related to a recent cancer transaction.
Now the pharmaceutical giant expects its adjusted financial profit in 2025 to be from $ 20.78 to $ 22.28 per share, which compared to previous $ 22.50 to $ 24. Eli Lily said the editorial board reflects the $ 1.57 billion agreement fee recorded in the first quarter, which is primarily associated with the acquisition of a certain oral cancer cancer with Scorpion Therapeutics.
The company supported its financial instructions in 2025 for sales of $ 58 billion to $ 61 billion. Eli Lily said
In an interview with CNBC CEO Eli Lily Dave Rix said the company and other drug manufacturers are already announced Investing in US productionWhat is one of the stated goals of the Trump administration.
“I think that the threat of tariffs is already returning critical supplies to important industries, chips and pharmaceuticals,” Rix said. “So, we need to accept (tariffs?) I’m not so sure.”
He added that Eli Lily wants to see the constant reduction of tax rates in the US, especially 15% for domestic production. Ricks said lower taxes have forced many drug manufacturers in “low tax production, like Ireland Singapore and Switzerland, and this can return if there is an economic stimulus.”
Blockbuster treatment blockbuster Eli Lily Montjar headed expectations for the first quarter, increasing $ 3.84 billion. This is a tremendous 113% from the same period ago.
Zepbound drug drugs also won estimates by booked $ 2.31 billion for the quarter. This is more than four times, $ 517.4 million that the treatment brought a year ago when it has just entered the US market.
Analysts expected Mounjaro and Zepbound to receive $ 3.81 billion and $ 2.28 billion, respectively, according to Streitaccount estimates.
The company’s shares fell 5% on Premarket.
That’s what Eli Lily reported for the first quarter compared to what Wall -Rate was waiting, based on a LSEG analyst poll:
- Profit per share: $ 3.34 adjusted against $ 3.02 expected
- Income: 12.73 billion dollars against $ 12.67 billion expected
The company has placed a profit in the first quarter of $ 12.73 billion, which is 45% compared to the same period ago.
Sales in the US jumped 49% to $ 8.49 billion. Eli Lily said it was due to an increase in 57% – or the number of recipes or divisions – for Zepbound and Mounjaro. This partially offset the lower drug prices, the company notes.
The pharmaceutical giant booked a net profit of $ 2.76 billion, or $ 3.06 per share for the first quarter. This is compared with a net profit of $ 2.24 billion, or $ 2.48, a year earlier.
With the exception of disposable items related to the price of intangible assets and other adjustments, for the first quarter Eli Lily placed a $ 3.34 profit per share per share.
Over the last year, the US demand has still exceeded Zepbound and Mounjaro. Both the so -called procedures for the incretin imitate certain intestinal hormones to delay the human appetite and regulate blood sugar.
The popularity of these injection drugs made Eli Lily and her competitor Novo nordisk To invest billions to increase production capacity for their procedure.
These efforts seem to pay off: Nutrition Administration and Medicines in December confirmed your decision To announce a Tirzepatide deficit in the US – the active substance in Zepbound and Mounjaro – is over. This decision is effectively banned by many Complex pharmacies from marketing and selling cheaper, unauthorized versions of Tirzepatide.
This story develops. Please check the updates.
